ClinicalTrials.gg
CompletedNCT01859962Updated Nov 25, 2015

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

A Phase 2 interventional study of PPI-668 and BI 207127 Dose 1 in Chronic Hepatitis C, sponsored by Presidio Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-25.

Sponsored by Presidio Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 256 studies in Hepatitis C, Chronic with a site in United States — none open to participants now, 3 under way, none of them phase 3. Hepatitis C, Chronic · United States.

Enrollment
154th of 220
38 · median 89
Started
2013
with 16 others
Phase 2
84 of 256
none open now
Registered
185th of 256
by date

Among the 256 studies in Hepatitis C, Chronic with a site in United States, this one is the 154th largest by enrollment of the 220 interventional ones that give a count, is one of 17 that started in 2013, is one of 84 in phase 2, and was the 185th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 256 studies in Hepatitis C, Chronic with a site in United States is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 256 studies in Hepatitis C, Chronic with a site in United States as a file.
02

Study summary

This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.

03

Conditions studied

  • Chronic Hepatitis C

Keywords

  • Liver diseases
  • Virus diseases
  • Ribavirin
  • protease inhibitor
  • NS5B polymerase inhibitor
  • NS5A inhibitor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 to 65 years of age; if females are of , then they must be willing to use two non-hormonal methods of
  2. Body weight greater than 40 kg and less than 125 kg
  3. Clinical diagnosis of chronic
  4. Treatment-naïve for hepatitis C: no previous treatment with interferon, pegylated interferon, ribavirin, telaprevir, boceprevir, or any therapies for hepatitis C
  5. No symptoms or signs of intercurrent illness at Screen (other than those attributable to hepatitis C)
  6. No abnormalities in the 12-lead at Screen
  7. Signed prior to trial participation.

Exclusion criteria

Exclusion Criteria:

  1. Seropositive for antibody or Surface Antigen at Screen
  2. Liver disease due to causes other than chronic infection
  3. Symptoms or signs of decompensated liver disease, or evidence of cirrhosis
  4. Any medical condition that may interfere with the absorption, distribution or elimination of study drugs
  5. Poorly controlled or unstable hypertension at Screen.
  6. , unstable cardiovascular or pulmonary disease, including cardiovascular or pulmonary disease requiring pharmacologic intervention other than anti-hypertensive medications, statins, and/or prophylactic aspirin (or similar anticoagulant).
  7. Red blood cell disorder, including (but not limited to): thalassemia major or minor, sickle cell anemia.
  8. Diabetes Mellitus treated with insulin or hypoglycemic agents
  9. History of asthma requiring hospital admission within the preceding 12 months
  10. History of alcohol abuse or illicit drug use which could interfere with a patient's compliance with the protocol requirements, or with the safety or efficacy assessments in this study
  11. Patients requiring treatment, during this study, with any of the medications on the restricted medications list (provided in the investigator site file), are not eligible for this study due to considerations of possible drug interactions with the study drug regimen.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin

    PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination

    Drug: PPI-668 · Drug: BI 207127 Dose 1 · Drug: Faldaprevir · Drug: Ribavirin

  • Active comparator
    PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin

    PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination

    Drug: PPI-668 · Drug: BI 207127 Dose 2 · Drug: Faldaprevir · Drug: Ribavirin · Drug: BI 207127 Placebo

  • Active comparator
    PPI-668, BI 207127 Dose 1, and Faldaprevir

    PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination

    Drug: PPI-668 · Drug: BI 207127 Dose 1 · Drug: Faldaprevir

Interventions

06

What researchers measure

Primary outcomes

  1. the proportion of patients achieving sustained viral response (SVR)

    Time frame: 12 weeks after the end of treatment

Secondary outcomes

  1. Proportion of patients with "virologic relapse" post-treatment, defined as confirmed and quantifiable (>LLOQ) serum HCV RNA in a patient who achieved non-detectable serum HCV RNA by the end of treatment

    Time frame: up to 24 weeks post-treatment

  2. Proportion of patients with confirmed viral breakthrough during study treatment

    "Confirmed viral breakthrough" is defined as a \> 1 log increase in HCV RNA from post-Baseline nadir value or confirmed increase in HCV RNA ≥LLOQ if HCV RNA previously declined to \<LLOQ (detected or not detected), during the 12-week study treatment period

    Time frame: up to 12 weeks of study treatment

  3. Proportions of study participants who receive at least one dose of study drug and who prematurely discontinue study treatment, and proportions prematurely discontinuing treatment for clinical adverse events or laboratory abnormalities

    Time frame: up to 12 weeks of study treatment

  4. Proportions of study participants experiencing treatment-emergent adverse events (serious and non-serious) considered to be possibly or probably attributable to study treatment, overall and by body system

    Time frame: up to 12 weeks of study treatment

07

Study locations

1 site
  • Quest Clinical Research
    San Francisco, California 94115, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2013
First posted
May 22, 2013
Start
May 2013
Primary completionActual
May 2014
CompletionActual
Dec 2014
Results delay requested
Oct 20, 2015
Last update
Nov 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01859962
Lead sponsor
Presidio Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 22, 2013
Start date
May 2013
Primary completion
May 2014
Completion
Dec 2014
Last update
Nov 25, 2015

Study contacts

Nathaniel Brown, MD
study director · Presidio Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion